Climate footprint of industry-sponsored clinical research: an analysis of a phase-1 randomised clinical study and discussion of opportunities to reduce its impact.

This study aims to calculate the global warming potential, in carbon dioxide (CO2) equivalent emissions, from all in-scope activities involved in a phase-1 clinical study. Retrospective analysis. Internal data held by Janssen Pharmaceuticals. Janssen-sponsored TMC114FD1HTX1002 study conducted between 2019 and 2021. Measure CO The CO Decentralised trial models which seek to bring clinical trial operations closer to the participant offer opportunities to reduce participant travel. The electrification of sponsor vehicle fleets and society's transition towards electric vehicles may result in further reductions. NCT04208061.

Informations de copyright

© Author(s) (or their employer(s)) 2024. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ.

Déclaration de conflit d'intérêts

Competing interests: JKL is an employeed of Janssen Pharmaceuticals and a member of the faculty at Delft University of Technology. RA is an employee of Environmental Resource Management. MC is an employee of Environmental Resource Management. TC is an employee of Environmental Resource Management. WDS is an employee of Janssen Pharmaceuticals, NV, a subsidiary of Janssen Pharmaceuticals. JF is a faculty member at Delft University of Technology. KR is an employee of Janssen Pharmaceuticals, NV, a subsidiary of Janssen Pharmaceuticals.